Stocks to Watch for September 24: NTPC, Bharat Dynamics, Exide Industries, Concord Biotech and more

GHCL Ltd | India's second-largest soda ash producer, GHCL Ltd, on Wednesday (September 23) said the company was declared the preferred bidder for the composite licence after an e-auction conducted by the Commissioner of Geology and Mining, Government of Gujarat.

Exide Industries Ltd | Battery maker Exide Industries Ltd on Wednesday (September 23) announced the completion of commissioning of Phase-I of its 6 GWh lithium-ion cell manufacturing facility by its material subsidiary, Exide Energy Solutions Ltd (EESL).

Bharat Dynamics Ltd | The Ministry of Defence has signed an ₹810.79 crore contract with Bharat Dynamics Ltd (BDL) for 160 Satellite Smart Anti-Airfield Weapons (SAT-SAAW) and associated equipment for the Indian Air Force, in another boost to India’s push for indigenous defence manufacturing.

NTPC | The firm has paid a final dividend of ₹3,393.83 crore for the financial year 2025-26, equivalent to 35% of the company’s paid-up equity share capital. The payment was made in addition to the first and second interim dividends for FY 2025-26, amounting to ₹2,666.58 crore each.

ESAF Small Finance Bank Ltd | Private lender on Wednesday (September 23) said its board has approved raising up to ₹500 crore through private placement of NCDs to augment Tier II Capital.

Sedemac Mechatronics | Investors, including A91 Emerging Fund, Xponentia Opportunities Fund and HDFC Life Insurance, are set to offload up to 44.3 lakh shares, or a 10% stake, in Sedemac Mechatronics through a block deal to raise ₹1,329 crore. The floor price for the deal has been set at ₹3,000 per share, representing a discount of up to 1.2% to the current market price, with a 60-day lock-in on further sale of the shares.

Avantel | The firm bags ₹177.35 crore order from Zetwerk Manufacturing Businesses for the supply of satellite equipment.

Concord Biotech | Its board has approved a 1:1 bonus share issue, rewarding shareholders with one additional equity share for every fully paid-up share held, subject to shareholder approval.

Jagsonpal Pharmaceuticals Ltd | The firm said it will acquire the wellness portfolio of Group Pharmaceuticals Ltd for a total consideration of up to ₹46.7 crore through a slump sale.